| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0009-9236(03)00060-2 |
| P698 | PubMed publication ID | 12811365 |
| P2093 | author name string | Hiroshi Suzuki | |
| Hiroyuki Kusuhara | |||
| Yuichi Sugiyama | |||
| Hiroshi Takane | |||
| Shin Irie | |||
| Ichiro Ieiri | |||
| Takeshi Hirota | |||
| Shun Higuchi | |||
| Kenji Otsubo | |||
| Akinori Urae | |||
| Miyuki Kimura | |||
| Kiyoshi Kawabata | |||
| Yoko Urasaki | |||
| Yohei Nishizato | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 554-65 | |
| P577 | publication date | 2003-06-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics | |
| P478 | volume | 73 |
| Q38204184 | A current approach to statin intolerance |
| Q34360031 | Adaptive hepatic and intestinal alterations in mice after deletion of NADPH-cytochrome P450 Oxidoreductase (Cpr) in hepatocytes |
| Q57314076 | Amiodarone Interacts with Simvastatin but not with Pravastatin Disposition Kinetics |
| Q39145949 | An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure |
| Q36265658 | Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport |
| Q37808376 | Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans |
| Q37331947 | Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review |
| Q46378129 | Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy |
| Q35135638 | Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy |
| Q82922415 | Association of intergenic polymorphism of organic anion transporter 1 and 3 genes with hypertension and blood pressure response to hydrochlorothiazide |
| Q84371927 | Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure |
| Q64938465 | CYP2C9 and OATP1B1 genetic polymorphisms affect the metabolism and transport of glimepiride and gliclazide. |
| Q50644999 | Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. |
| Q24612653 | Clinical assessment incorporating a personal genome |
| Q37230383 | Clinical characterization and molecular mechanisms of statin myopathy |
| Q38160088 | Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions |
| Q37818151 | Clinical implications of pharmacogenetic variation on the effects of statins. |
| Q36426816 | Clinical implications of pharmacogenomics of statin treatment |
| Q38056878 | Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption |
| Q36303810 | Combinatorial pharmacogenetics |
| Q40135603 | Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations |
| Q51696345 | Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition. |
| Q39743950 | DNA methylation profiles of organic anion transporting polypeptide 1B3 in cancer cell lines |
| Q38302225 | Dealing with the complex drug-drug interactions: towards mechanistic models. |
| Q80997948 | Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy |
| Q83641285 | Development of a model for prediction of coronary atherosclerotic regression: evaluation of high-density lipoprotein cholesterol level and peripheral blood monocyte count |
| Q57825140 | Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin |
| Q46813708 | Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide |
| Q41986919 | Direct and rapid genotyping of SLCO1B1 388A>G and 521T>C in human blood specimens using the SmartAmp-2 method |
| Q36701911 | Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146. |
| Q38109095 | Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. |
| Q91620854 | Drug-drug-gene interactions and adverse drug reactions |
| Q39985485 | Dyslipidemia in Special Ethnic Populations |
| Q35573543 | Dyslipidemia in special ethnic populations |
| Q53432800 | Effect of HMGCR variant alleles on low-density lipoprotein cholesterol-lowering response to atorvastatin in healthy Korean subjects. |
| Q35827882 | Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide |
| Q33776950 | Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants |
| Q37724381 | Efflux and uptake transporters as determinants of statin response. |
| Q93119620 | Enantiospecific Pharmacogenomics of Fluvastatin |
| Q38084901 | Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism |
| Q44737065 | Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans |
| Q38707798 | Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis |
| Q34042444 | Expression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver |
| Q57825157 | Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population |
| Q36623470 | Frequencies of single-nucleotide polymorphisms and haplotypes of the SLCO1B1 gene in selected populations of the western balkans |
| Q43940364 | Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method |
| Q33673141 | Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4). |
| Q48792346 | Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. |
| Q51272853 | Genetic Variations in Bilirubin Metabolism Genes and Their Association with Unconjugated Hyperbilirubinemia in Adults. |
| Q28478042 | Genetic background of patients from a university medical center in Manhattan: implications for personalized medicine |
| Q26823434 | Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review |
| Q34878913 | Genetic polymorphism of the human organic solute carrier protein 1 (hOSCP1) gene in Japanese patients with non-viral liver carcinoma |
| Q37481450 | Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs |
| Q42185876 | Genotyping of OATP2 Variants in a Group of Malaysian Neonates Using High-Resolution Melting Analysis |
| Q37298808 | Germline prognostic markers for urinary bladder cancer: obstacles and opportunities. |
| Q39340828 | Global analysis of genetic variation in SLCO1B1. |
| Q50987232 | HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol. |
| Q37608527 | HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice |
| Q37680968 | Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects |
| Q36606137 | Hepatobiliary transporters and drug-induced cholestasis |
| Q40068634 | Hepatocyte nuclear factor 1 alpha is a factor responsible for the interindividual variation of OATP1B1 mRNA levels in adult Japanese livers |
| Q54482207 | Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. |
| Q99604573 | Identification of Glycochenodeoxycholate 3-O-Glucuronide and Glycodeoxycholate 3-O-Glucuronide as Highly Sensitive and Specific OATP1B1 Biomarkers |
| Q48239282 | Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. |
| Q47113473 | Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population |
| Q36986507 | Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges |
| Q34612244 | Impact of OATP transporters on pharmacokinetics |
| Q38663481 | Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. |
| Q38003174 | Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development. |
| Q35575700 | Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution |
| Q37811961 | In Vitro and In Vivo Evidence of the Importance of Organic Anion Transporters (OATs) in Drug Therapy |
| Q35607723 | Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients |
| Q53568394 | Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. |
| Q36687277 | Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans |
| Q39236582 | Influence of serum in hemodialysis patients on the expression of intestinal and hepatic transporters for the excretion of pravastatin |
| Q52933882 | Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels. |
| Q36981855 | Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. |
| Q40141881 | Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans |
| Q42672191 | Interethnic comparisons of important pharmacology genes using SNP databases: potential application to drug regulatory assessments |
| Q39034284 | Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). |
| Q35430039 | Isolation of modulators of the liver-specific organic anion-transporting polypeptides (OATPs) 1B1 and 1B3 from Rollinia emarginata Schlecht (Annonaceae). |
| Q37728163 | Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients |
| Q48092928 | Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs |
| Q29616802 | Membrane transporters in drug development |
| Q36653405 | Molecular insights into the structure-function relationship of organic anion transporters OATs |
| Q51304317 | Nanomemulsion of megestrol acetate for improved oral bioavailability and reduced food effect. |
| Q54216256 | No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. |
| Q36536042 | No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone |
| Q40054814 | Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNP c.1929A>C. |
| Q57500316 | OATP1B1 POLYMORPHISM IS A MAJOR DETERMINANT OF SERUM BILIRUBIN LEVEL BUT NOT ASSOCIATED WITH RIFAMPICIN-MEDIATED BILIRUBIN ELEVATION |
| Q37489569 | OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis |
| Q27001267 | OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies |
| Q64932041 | Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology. |
| Q47361769 | Organic Ion Transporters and Statin Drug Interactions |
| Q57500318 | Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients |
| Q37938905 | Overview of pharmacogenetics |
| Q28068014 | Pediatric Statin Administration: Navigating a Frontier with Limited Data |
| Q38049379 | Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children |
| Q37182212 | PhRMA white paper on ADME pharmacogenomics. |
| Q42726145 | PharmGKB very important pharmacogene: SLCO1B1. |
| Q34680467 | Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins |
| Q80135532 | Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy |
| Q102384319 | Pharmacogenetics at Scale: An Analysis of the UK Biobank |
| Q34777362 | Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney |
| Q35297067 | Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response |
| Q40225504 | Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations |
| Q24676890 | Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy |
| Q38933314 | Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review. |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q35956177 | Pharmacogenetics-based new therapeutic concepts |
| Q27692687 | Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine |
| Q36335716 | Pharmacogenomics of cholesterol-lowering therapy |
| Q36441493 | Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy |
| Q38307994 | Pharmacogenomics of glinides. |
| Q36416907 | Pharmacogenomics of human OATP transporters |
| Q40500528 | Pharmacokinetic Modeling and Monte Carlo Simulation to Predict Interindividual Variability in Human Exposure to Oseltamivir and Its Active Metabolite, Ro 64-0802. |
| Q34787395 | Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin |
| Q34599850 | Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. |
| Q46472687 | Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism |
| Q46772973 | Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis. |
| Q36146910 | Pharmacokinetic variability of anticancer agents |
| Q35827696 | Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes |
| Q57684574 | Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions |
| Q81721908 | Physiology, structure, and regulation of the cloned organic anion transporters |
| Q43810170 | Polymorphisms in the organic anion transporting polypeptide genes influence liver parenchymal enhancement in gadoxetic acid-enhanced MRI. |
| Q35080119 | Potential role of organic anion transporting polypeptide 1B1 (OATP1B1) in the selective hepatic uptake of hematoporphyrin monomethyl ether isomers |
| Q38855314 | Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS). |
| Q33437736 | Prediction of hepatic clearance in human from in vitro data for successful drug development |
| Q38233298 | Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved |
| Q36365166 | Professor Yuichi Sugiyama: A Brilliant, Creative, Amicable, Charming, and Humorous Pharmaceutical Scientist. |
| Q43272335 | Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic Information on SLCO1B1 and ABCC2 polymorphisms |
| Q54654987 | Rapid genotyping of the OATP1B1 polymorphisms A388G and T521C with real-time PCR FRET assays. |
| Q46974116 | Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencing |
| Q37121662 | Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. |
| Q37184530 | Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans |
| Q34117674 | Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8) |
| Q38001074 | Risk and preventive factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive review |
| Q35088420 | Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. |
| Q37074085 | Role of OATP transporters in the disposition of drugs |
| Q36544966 | Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination |
| Q41512597 | Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States |
| Q34579035 | SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers |
| Q36024636 | SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients |
| Q36184009 | SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals. |
| Q34574500 | Safety and efficacy of statins in Asians |
| Q37778668 | Serum Bilirubin and Genes Controlling Bilirubin Concentrations as Biomarkers for Cardiovascular Disease |
| Q34340098 | Several Conserved Positively Charged Amino Acids in OATP1B1 are Involved in Binding or Translocation of Different Substrates |
| Q90028031 | Simultaneous Determination of Five Cytochrome P450 Probe Substrates and Their Metabolites and Organic Anion Transporting Polypeptide Probe Substrate in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry |
| Q40349386 | So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics |
| Q37951651 | Statin dose in Asians: is pharmacogenetics relevant? |
| Q34608646 | Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testing |
| Q36192738 | Statin response and pharmacokinetics variants |
| Q33786577 | Synergistic interaction between genetics and disease on pravastatin disposition |
| Q36212769 | Systems-ADME/Tox: resources and network approaches |
| Q35817004 | The MDR1 (ABCB1) gene polymorphism and its clinical implications |
| Q35793721 | The complexities of hepatic drug transport: current knowledge and emerging concepts. |
| Q37175829 | The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range |
| Q81241502 | The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1 |
| Q46607014 | The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite |
| Q37955160 | The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance. |
| Q34613443 | The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. |
| Q34631971 | The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins |
| Q37537018 | The role of transporters in the pharmacokinetics of orally administered drugs |
| Q41810909 | Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters |
| Q41706349 | Toward Prospective Prediction of Pharmacokinetics in OATP1B1 Genetic Variant Populations |
| Q37627544 | Transporter pharmacogenetics and statin toxicity |
| Q46783215 | Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase |
| Q36123304 | Transporters and their impact on drug disposition |
| Q46038296 | UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. |
| Q38050686 | Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. |
| Q50641149 | Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. |
| Q33714593 | Xenobiotic, bile acid, and cholesterol transporters: function and regulation. |
| Q52936666 | [Implications of pharmacogenetics in every-day practice]. |
| Q40189578 | effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers |
Search more.